CytomX Q1 2022 revenue $17.1M; cash $263M; pipeline data expected H2 2022

CytomX Therapeutics, Inc.

Cash, equivalents and investments $263M at March 31, 2022, down from $305M at Dec 31, 2021.
Total revenue $17.1M for Q1 2022, up from $16.0M in Q1 2021, primarily from AbbVie collaboration.
R&D expenses $30.6M (up $8.2M YoY); G&A $10.5M (up $1.3M YoY); operating loss implied.
Phase 2 praluzatamab ravtansine: Arm A enrollment complete; initial data for Arms A & B in H2 2022.
CX-2029 completed enrollment in squamous NSCLC cohort; data update expected in H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.